Masimo's Medical Watch Receives FDA Clearance

Masimo, a global medical technology company received FDA clearance for its medical watch.

Image Credits: Business Wire

Masimo announced that its Masimo W1 medical watch has received FDA 510(k) clearance for over-the-counter (OTC) and prescription use(Rx). Masimo W1 is the first FDA-cleared watch to provide continuous real-time oxygen saturation (SpO2) and pulse rate (PR) for OTC and Rx use. The FDA clearance expands the indications for the Masimo W1 in the U.S. as a medical devic­­­e for use by adults in hospitals, clinics, long-term care facilities, and in the home. Developed to be comfortable and lifestyle-friendly, the MasimoW1 medical watch empowers users with untethered continuous pulse oximetry as they move about their lives – no matter where they are.

The clinical power of the Masimo W1 comes from its integrated Masimo MW-1 sensor, hardware, and software module, which incorporates over 30 years of Signal Extraction Technology® pulse oximetry knowledge into a single wearable module. It has an integrated optical sensor and electrocardiogram (ECG) electrode pads that can be used to detect physiological signals. The Masimo MW-1 module also processes these signals using Masimo’s proprietary signal processing algorithms to output high-resolution SpO2, PR, perfusion index (Pi), and heart rate (HR) from an ECG. The continuous pulse oximetry data, under the care of a physician, can give greater visibility of changes in oxygen saturation to help patients better manage their oxygen levels daily. Managing oxygen levels can be prescribed for recovery after surgery, managing chronic breathing conditions (e.g. COPD), and for patients with congenital heart failure (CHF).

The continuous data from the Masimo MW-1 module is displayed in real-time on the Masimo W1 watch touchscreen in an easy-to-interpret format. To help individuals identify low oxygen saturation, high pulse rate, or low pulse rate, the SpO2 and PR values are displayed in red when they fall outside of their normal ranges.

Joe Kiani, Founder and CEO of Masimo, said, “Clinicians at numerous prestigious institutions in Europe and the Middle East are already using Masimo W1 in a variety of innovative ways. For example, Cambridge University Hospitals in England is using it to expand its Virtual Health program to support more confident patient discharge. The Department of Anesthesiology at CHUV in Lausanne, Switzerland is using Masimo W1 on preoperative patients, to help anesthesiologists better understand the physiology and areas to improve for each patient they care for in the hospital, prior to surgery. We are excited about the hospital-to-home innovations the Masimo W1 can bring to the U.S., with this FDA clearance, and the empowerment of patients at home.”

Related: World's First Health Tracker Powered by the User

The Masimo W1 and the integrated Masimo MW-1 module are also intended for the spot-checking of functional oxygen saturation of arterial hemoglobin (SpO2) and pulse rate (PR). The Masimo W1 and the integrated MasimoMW-1 Module are indicated for adults in hospitals, clinics, long-term care facilities, and homes.

About Masimo

Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. In addition, Masimo Consumer Audio is home to eight legendary audio brands, including Bowers & Wilkins, Denon, Marantz, and Polk Audio.

Sam Draper
December 1, 2023

Innovation of the Month

Do you want to discover more, visit the website
Visit Website

Other news

Fertility Tracking App Flo Raises $50M Series B Round, Bringing Company Valuation to $800M

Fertility tracking app Flo announced it closed $50M in a Series B financing, bringing the total ...

How Wearables Will Make Workplaces of the Future More Distributed and Networked

Smart glasses and head-mounted displays have found their way into corporate operations in recent...

tooz Becomes AR/VR Competence Center of ZEISS

With the acquisition of shares held by Deutsche Telekom, ZEISS Ventures is now sole owner of tooz.

Wyss Institute Researchers Develop “eRapid” Platform for Creating Low-Cost, Handheld Electrochemical Devices

Millions of people with diabetes around the world use handheld electrochemical sensors...
Discover more